SUMMARY Twenty six consecutive patients with neuroleptic-induced Parkinson's syndrome (NIPS) are described. Their median age was 61 years, 60% were female, and most had received chronic neuroleptic medication for psychiatric indications. The clinical features were indistinguishable from idiopathic Parkinson's disease, except for the presence of co-existing orofacial chorea, limb dyskinesia or akathisia which provided an aetiological clue in 11 cases. Complete resolution of NIPS occurred in only two patients, one of whom later developed Parkinson's disease. Sixteen patients were treated with 300-1000 mg levodopa/benserazide for up to 4 years with few adverse effects but therapeutic response was disappointing.
It is widely recognised that neuroleptic drugs can induce a state of Parkinsonism, a major adverse reaction attributed to antagonism at striatal dopamine receptors. In one of the largest series, Ayd' reported an overall incidence of 15% for neuroleptic-induced Parkinson's syndrome (NIPS) in over 3700 patients, and more recent experience has suggested a prevalence of up to 40%. 2 3 It is important to distinguish between the prevalence of extra-pyramidal signs and actual morbidity attributable to the medication34 but there can be no doubt that NIPS causes significant functional disability in some cases.
There is no generally accepted agreement regarding management. Relapse rates are higher amongst schizophrenic patients if anti-psychotic treatment is withdrawn, hence chronic maintenance therapy is warranted in many cases.56 The value of anticholinergic drugs has probably been over-estimated, particularly when administered routinely,2 4 and there is some evidence to suggest that NIPS may remit spontaneously even when the neuroleptic drug is continued, perhaps because of delayed receptor supersensitivity.7
The effects of levodopa have seldom been examined in NIPS despite a few encouraging reports.8 -10 This may partly reflect assumptions about competitive an-tagonism between the two forms of drug treatment and also fears concerning exacerbation of psychosis,'' 12 although we and others13 14 have safely used levodopa in psychiatric illness in attempts to ameliorate tardive dyskinesia. Because of ethical and safety considerations in an outpatient population with mainly psychiatric illness, a double-blind placebocontrolled study would have been difficult to justify and to carry out. We therefore devised an open pilot study to assess the safety and possible efficacy of levodopa given in combination with benserazide.
The present report summarises the clinical features of a group of patients believed to have NIPS, and describes the results of various management strategies including the use of levodopa.
Patients and Methods
We reviewed 26 consecutive patients (16 Other features: orofacial dyskinesia OD; limb dyskinesia LD; akathisia AK; dystonia DT.
Extra-pyramidal features on clinical examination were assessed using the Webster rating scale,"5 and functional disability recorded using the Northwestern University Disability Scale (NUDS). 15 The distribution and severity of any dyskinesia was also recorded. Twenty one patients in whom Parkinsonism was causing significant disability were identified for further management. Where possible, the dopamine receptor antagonist was gradually withdrawn, under joint supervision with psychiatric colleagues if appropriate. In those who did not improve, or in those whose psychiatric illness was considered too unstable to permit withdrawal, a trial of anti-Parkinsonian medication was given. Provided that tardive dyskinesia and akathisia were absent or only mild, the dosage of any existing anti-cholinergic drug was increased to maximum tolerated levels, or benzhexol introduced in doses increasing to 8 mg daily. If anti-cholinergic drugs were ineffective or contraindicated, treatment with levodopa + benserazide ("Madopar") was gradually introduced and the dosage cautiously increased at monthly intervals according to clinical response. Patients were examined on each attendance by one of the authors.
Results
Clinical observations at presentation ( 9 The management of NIPS remains largely empirical. Obviously the best course is withdrawal of the offending drug as soon as the complication is identified. Chronic administration of anti-emetics or vestibular sedatives is very seldom warranted. The dose of neuroleptic drugs can often be reduced after control of an acute psychotic illness is established, and the indications for maintenance treatment should be continually reviewed. However, there are many patients in whom drug therapy cannot be safely discontinued. Furthermore, drugs of this class typically have cumulative effects even if depot formulations are not used and the severity of the syndrome may be sufficient to require urgent intervention.
Traditionally, anti-cholinergic agents have been used either as prophylaxis against NIPS or in its management. Surprisingly, there is little evidence of their efficacy. Thus few psychiatric patients show any deterioration in their Parkinsonism following withdrawal of existing anti-cholinergic drugs,24 and in some of these the deterioration may be only technically rather than functionally relevant.3 A variety of important complications have been recognised7 and many authorities have concluded that these agents have only a very limited role. 34 Clinical trials in this area are notoriously difficult to conduct and interpret,7 but in at least one doubleblind study amantadine and orphenadrine were not superior to placebo.26 Moreover, in some of the early double-blind, placebo-controlled trials establishing the value of maintenance therapy with neuroleptics, "blind" psychiatrists were free to prescribe anticholinergic medication which they did equally amongst the placebo and active treatment groups.25 27 28 This confirms the subjective nature of perceived extra-pyramidal features in patients with often severe psychiatric illness which may have its own concomitant motor disorder. '7 Beneficial changes in mental state have been claimed with levodopa administered to psychiatric patients in low doses. 29 -31 This may in part be due to non-specific alerting effects since larger doses have been associated with an increased frequency of psychotic features. 11 12 32-3 There are few reports of the use oflevodopa in NIPS, and only one where a peripheral decarboxylase inhibitor has also been used.
Despite one report of universal improvement transiently in all 40 patients following iv injection of levodopa,8 results of oral therapy have generally been disappointing. McGeer et a133 described only mild benefits in three out of seven patients, while Fleming et a134 reported no effect in three patients. Kimura et al'0 confined their analysis to the improvement in facial mobility in nine cases. No significant benefit occurred in 26 patients treated prophylactically with up to 600 mg levodopa plus benserazide for 6 months when compared with a placebo-treated group. 35 No adverse psychiatric effects were reported in any of these studies.
Apart from increased anxiety in one patient and potentiation of pre-existing dyskinesia in two others, we encountered no significant complications during levodopa therapy. However, beneficial effects were disappointing. Only one patient, the 26 year old man, made an unequivocally complete recovery. One other (PW) relapsed, implying the presence of underlying Parkinson's disease. In only three of the other eight from whom the offending drug was withdrawn was there a significant functional improvement after up to 39 months, some or all of which could have been attributable to withdrawal rather than levodopa. In only two cases, who continued receiving neuroleptic medication, could benefit reasonably be ascribed to levodopa.
Perhaps of greater significance is the fact that, of 21 patients with disabling NIPS, only two (JS, HY) have had complete resolution, and 19 remain incapacitated despite our management strategies. This naturally questions the prevailing assumption about reversibility of NIPS implicit in the simple mechanism of pharmacological antagonism.
Prolonged delay for up to 18 months in resolution of NIPS following drug withdrawal is well described,36 but it has been estimated37 that only about 1% of cases fail to remit and that these few cases were likely to have concomitant Parkinson's disease as well. However, most of our patients remained Parkinsonian despite discontinuation of the apparent cause and use of anti-Parkinsonian drugs.
This experience is similar to that of Stephen and Williamson, '9 
